Altimmune’s GLP-1-based shot cuts drinking in patients with alcoholism

Phase 2positivepemvidutidePositive

AI Analysis

Summary

Altimmune announced positive Phase 2 RECLAIM trial results showing its GLP-1/glucagon agonist pemvidutide reduced drinking in patients with moderate-to-severe alcohol use disorder compared to placebo.

Clinical Trial Data

Phase

Phase 2

Primary Endpoint

Met

Outcome Details

GLP-1/glucagon agonist reduced drinking in patients with moderate-to-severe alcohol use disorder

Importance:6/10

Sentiment:

0.75

GLP-1Alcohol Use DisorderPhase 2 DataRECLAIM Trial

Related Companies

$ALT

Read the original article

Published by Endpoints News on July 28, 2026 11:00 AM

Read Original